Gao Haonan, Sai Yanyan, Shang Ruirui, Zhong Xia, Kong Linghui, Liu Jie, Wang Kedong
First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
University Town Hospital, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Front Pharmacol. 2025 May 19;16:1595160. doi: 10.3389/fphar.2025.1595160. eCollection 2025.
Post-stroke depression (PSD) is a common sequela of stroke and a neuropsychiatric disorder associated with poor recovery, significant cognitive deficits, and reduced quality of life. Many natural products (NPs), known for their diverse biological activities, low toxicity, as well as multi-targeting capabilities, offer distinct advantages in PSD treatment by modulating pathological mechanisms. However, a comprehensive summary of the pathological mechanisms of PSD and the molecular mechanisms of NPs intervention is currently lacking. This review aimed to investigate the pathological mechanisms of PSD. It also explored the pharmacological mechanisms by which NPs exerted anti-PSD effects and in-depth discussion the limitations of current studies. Furthermore, it proposed novel methodologies for future preclinical and clinical translation in PSD research.
中风后抑郁症(PSD)是中风常见的后遗症,是一种与恢复不佳、显著认知缺陷及生活质量下降相关的神经精神障碍。许多天然产物(NPs)以其多样的生物活性、低毒性以及多靶点作用能力而闻名,通过调节病理机制在PSD治疗中具有独特优势。然而,目前缺乏对PSD病理机制及NPs干预分子机制的全面总结。本综述旨在研究PSD的病理机制,探讨NPs发挥抗PSD作用的药理机制,并深入讨论当前研究的局限性。此外,还提出了PSD研究未来临床前和临床转化的新方法。